To　review　the　experience　in　transarterial　neoadjuvant　chemotherapy　of　malignant　fibrous　histiocytoma　(MFH)　in　soft　tissue　and　to　analyze　the　factors　related　to　prognosis　of　MFH　in　soft　tissue.　Between　September　1999　and　December　2011,　101　cases　of　MFH　in　soft　tissue　patients　treated　by　transarterial　administration　of　Cisplatin,　Adriamycin　and　Norcantharidin　were　divided　into　primary　group　and　recurrent　group,　and　the　clinical　documents　were　reviewed.　Nine　factors　that　might　affect　prognosis　such　as　age,　sex,　tumor　size,　tumor　site,　tumor　infiltration　depth,　recurrence　if　any,　pathological　type,　histologic　grade　and　histologic　response　of　chemotherapy　were　analyzed　statistically.　The　5-year　relapse-free　survival　rate　and　the　overall　survival　rate　were　70.5　and　75.0　%,　respectively,　in　the　primary　group;　56.1　and　57.9　%,　respectively,　in　the　recurrent　group.　Univariate　analysis　(log-rank　test)　showed　that　the　factors　affecting　the　prognosis　were　age　(P　=　0.03),　tumor　size　(P　=　0.01),　pelvic　tumor　(P　=　0.02),　recurrence　if　any　(P　=　0.004),　histologic　grade　(P　=　0.01),　and　histologic　response　to　chemotherapy　(P　=　0.007).　Multivariate　analysis　showed　that　the　major　factors　affecting　prognosis　were　pelvic　tumor　(P　=　0.01),　tumor　size　(P　=　0.002),　histologic　grade　(P　=　0.002),　recurrence　if　any　(P　=　0.0004),　and　histologic　response　to　chemotherapy　(P　=　0.008).　Transarterial　neoadjuvant　chemotherapy　can　significantly　increase　the　curative　efficacy　of　chemotherapy　and　survival　rate　in　MFH　treatment.